Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19426251rdf:typepubmed:Citationlld:pubmed
pubmed-article:19426251lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:19426251lifeskim:mentionsumls-concept:C0179926lld:lifeskim
pubmed-article:19426251pubmed:issue2lld:pubmed
pubmed-article:19426251pubmed:dateCreated2009-5-11lld:pubmed
pubmed-article:19426251pubmed:abstractTextVentricular assist devices are an important therapeutic option for advanced congestive heart failure. A left ventricular assist device (LVAD) can be implanted as a bridge to transplantation or for the purpose of destination therapy. LVADs improve end-organ function and reduce morbidity and mortality in appropriately selected patients. The development of axial flow pumps has overcome many of the limitations of the first-generation pulsatile flow LVADs. However, many complications of LVAD therapy remain. Treating these complications requires an understanding of LVAD physiology. Ongoing research is directed at reducing the incidence of many of these complications and may allow for wider use of LVADs.lld:pubmed
pubmed-article:19426251pubmed:languageenglld:pubmed
pubmed-article:19426251pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19426251pubmed:citationSubsetIMlld:pubmed
pubmed-article:19426251pubmed:statusMEDLINElld:pubmed
pubmed-article:19426251pubmed:issn1755-5914lld:pubmed
pubmed-article:19426251pubmed:authorpubmed-author:NakaYoshifumi...lld:pubmed
pubmed-article:19426251pubmed:authorpubmed-author:JordeUlrich...lld:pubmed
pubmed-article:19426251pubmed:authorpubmed-author:SayerGabrielGlld:pubmed
pubmed-article:19426251pubmed:issnTypePrintlld:pubmed
pubmed-article:19426251pubmed:volume27lld:pubmed
pubmed-article:19426251pubmed:ownerNLMlld:pubmed
pubmed-article:19426251pubmed:authorsCompleteYlld:pubmed
pubmed-article:19426251pubmed:pagination140-50lld:pubmed
pubmed-article:19426251pubmed:meshHeadingpubmed-meshheading:19426251...lld:pubmed
pubmed-article:19426251pubmed:meshHeadingpubmed-meshheading:19426251...lld:pubmed
pubmed-article:19426251pubmed:meshHeadingpubmed-meshheading:19426251...lld:pubmed
pubmed-article:19426251pubmed:meshHeadingpubmed-meshheading:19426251...lld:pubmed
pubmed-article:19426251pubmed:meshHeadingpubmed-meshheading:19426251...lld:pubmed
pubmed-article:19426251pubmed:meshHeadingpubmed-meshheading:19426251...lld:pubmed
pubmed-article:19426251pubmed:meshHeadingpubmed-meshheading:19426251...lld:pubmed
pubmed-article:19426251pubmed:meshHeadingpubmed-meshheading:19426251...lld:pubmed
pubmed-article:19426251pubmed:meshHeadingpubmed-meshheading:19426251...lld:pubmed
pubmed-article:19426251pubmed:year2009lld:pubmed
pubmed-article:19426251pubmed:articleTitleVentricular assist device therapy.lld:pubmed
pubmed-article:19426251pubmed:affiliationThe Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY, USA.lld:pubmed
pubmed-article:19426251pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19426251pubmed:publicationTypeReviewlld:pubmed